GSK Investigational Site

Łomża 18-400

0 studies enrolling now · 3 studies all time

What they study most

Asthma, Pulmonary Disease, Chronic Obstructive

Studies at this site

• A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD — Completed
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents — Completed